MidAmerica Neuroscience Institute

Lenexa, Kansas 66214

0 studies enrolling now · 16 studies all time

What they study most

Alzheimer's Disease, Central Neuropathic Pain, Clinically Isolated Syndrome, Cognition Disorders, Dementia, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis, Restless Legs Syndrome, Spasticity

Studies at this site

• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis — Completed
• A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis — Completed
• IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis — Stopped early
• Autologous T Cell Vaccine (TCV) for Multiple Sclerosis — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS) — Completed
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program — Completed
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis — Completed